FAQ

FAQ published on April 10, 2014
Dr. Cavalli discusses therapeutic options for an elderly patient, defined as 65 years and over, a demographic susceptible to lethal toxicity from agents.
FAQ published on April 10, 2014
Dr. von Tresckow discusses treatment options for relapsed/refractory Hodgkin lymphoma.
FAQ published on April 9, 2014
Dr. Tim Illidge discusses radiotherapy as part of a standard of care in Hodgkin lymphoma patients.
FAQ published on April 9, 2014
Dr. Steidl discusses microenvironments and the significance in the molecular pathogenesis of Hodgkin lymphoma.
FAQ published on March 21, 2014
Dr. Borchmann discusses the efficacy and safety of long-term treatment that includes involved field radiotherapy.
FAQ published on March 5, 2014
Dr. Engert discusses the treatment regimen BEACOPP escalated and the occurrence of acute leukemia and myelodysplasia after treatment.
FAQ published on March 5, 2014
Dr. Hutchings discusses the role of PET-CT for therapy in patients with relapsed/refractory Hodgkin lymphoma.
FAQ published on March 5, 2014
Dr. Andrew Zelenetz discusses the appropriateness of nonmyeloablative allogeneic SCT in the treatment patients with refractory Hodgkin lymphoma.
FAQ published on February 12, 2014
Dr. Federico discusses measuring tumor burden in Hodgkin lymphoma patients.
FAQ published on February 12, 2014
Dr. Andrew Evens discusses treatment options and specific risk factors associated with the elderly patient.
Page 5 of 7
Results 41 - 50 of 62

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved